Navigation Links
versus in Medical Technology

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

... significantly greater A1C reduction, weight loss versus weight gain and fewer episodes of hypoglycemia." ... was 4 percent with exenatide once weekly versus 19 percent with Lantus for patients on metformin ... and 20 percent with exenatide once weekly versus 44 percent with Lantus for patients on metformin ...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

... also significantly reduced SLE disease activity versus placebo based on a number of other measures, ... primary efficacy endpoint of superiority versus placebo at Week 52. A clinically and ... in both belimumab treatment groups, versus placebo, had their average prednisone dose ...

5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH

... of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin on progression of retinopathy in ... controlled study with insulin glargine versus NPH human insulin ," said lead investigator ... the retinal safety profile of Lantus(R) versus NPH in 1024 patients (Lantus(R) once daily: 515 ...

New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%

... prebiotics had an 80% survival rate to 24 months versus a 50% survival rate for the control group rats ... reductions in cholesterol and body weight versus the control group. Significantly, the ... has repeatedly shown synergistic health benefits versus the more common single-prebiotic fibers such as ...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

... with methotrexate plus placebo (0.29, 0.34 versus 1.1, respectively; p<0.001). In addition, ... plus placebo-treated patients (81%, 85% versus 67%, p less than or equal to 0.0001), as measured ... a post-hoc analysis of the AMBITION ( A ctemra versus M ethotrexate double- B lind I ...

Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

... to placebo (5 percent for tadalafil 40 mg, versus 16 percent with placebo)(4,5). Additionally, the ... mg were headache (42 percent for tadalafil 40 mg, versus 15 percent with placebo), myalgia (14 percent for tadalafil 40 mg, versus 4 percent with placebo) and flushing (13 percent ...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

... at 6, 12, 18 and 24 months for lorcaserin versus placebo were 2.1% vs. 1.9% (p=0.88), 2.7% vs. ... evaluated 10 mg of lorcaserin dosed twice daily versus placebo over a two-year treatment period in obese ... 10 mg of lorcaserin dosed once or twice daily versus placebo over a one-year treatment period in obese ...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

... five years) previously demonstrated by Avandia versus metformin and sulfonylurea in the ADOPT study. ... randomized to Avandia (61 events or 2.7 percent versus 29 events or 1.3 percent) (hazard ratio=2.10, 95 ... deaths from any cause (136 events or 6.1 percent versus 157 events or 7 percent for control) (hazard ...

Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry

... a single fixed dose of lurasidone 80 mg/day versus placebo. Lurasidone 80 mg/day produced statistically significant improvement versus placebo in both primary and secondary efficacy ... using the Barnes Akathisia Scale) for lurasidone versus placebo. Lurasidone was well-tolerated ...

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

... combination of vandetanib 100mg with docetaxel versus docetaxel alone. The study enrolled 1391 patients ... study evaluating vandetanib 100mg plus pemetrexed versus pemetrexed alone. The study enrolled 534 patients ... study evaluating the efficacy of vandetanib 300mg versus erlotinib 150mg. The study enrolled 1240 patients ...

Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women

... the Recurrence Score(R) was 53.6 percent in males versus 53.4 percent in females, intermediate risk of recurrence was 35.2 percent in males versus 36.3 percent in females, and high risk of recurrence was 11.2 percent in males versus 10.3 percent in females. Despite the ...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

... the median time to RECIST progression was 4.8, versus 2.8 for placebo.(11) BIBF 1120 is an oral ... Ingelheim Pharmaceuticals. "BIBW 2992 and BSC versus Placebo and BSC in Non-Small Cell Lung Cancer ... of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing ...

New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel

... in the CYP2C19 gene that reduced its function versus 9.8 percent (N=1048) in patients without a ... attack, or stroke by 19 percent (9.9 percent versus 12.1 percent), with an increased risk of major ... (3) Wiviott, S, Braunwald, E, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary ...

Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial

... in lung function from baseline of 6.6% (p=0.001 versus placebo). Lung function improved at week 6 and ... treated with Bronchitol and dornase alfa (p=0.008 versus placebo) and those being treated with Bronchitol alone (p=0.015 versus placebo). Consistent loss of lung ...

New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting

... and tolerability of pramipexole extended release versus the currently available pramipexole immediate ... release and immediate release formulations versus placebo after 18 weeks and 33 weeks of treatment, ... group, the mean change was -2.7 points at week 33 versus -4.2 points at week 18, a worsening of +1.5 ...

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease

... of percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery ... demonstrates that the cost effectiveness of PCI versus CABG depends largely on patient characteristics, ... the increase in repeat revascularization for PCI versus CABG was greatest -- CABG provided slightly more ...

Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis

... Significantly Suppressed Bone Turnover Markers versus Raloxifene in Postmenopausal Women with ... and nasopharyngitis in the arzoxifene group versus the raloxifene group, whereas significantly fewer ... About the " NEXT " Study Arzoxifene versus Raloxifene: 12-month Effects on Bone Mineral ...

Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C

... rates of serious and/or severe adverse events versus peginterferon alfa-2a - - Filing of global ... dose of albinterferon alfa-2b every two weeks, versus the treatment group receiving the standard dose ... Phase 3 Clinical Trials of Albinterferon Alfa-2b versus Peginterferon Alfa-2a HGS has conducted two ...

Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)

... treatment with the 25 mg dose and the 50 mg dose versus placebo (p < 0.01 for all comparisons). ... of 5.7 SBMs during the first week of treatment versus 1.6 SBMs per week during the baseline period. The increase in SBMs versus placebo was maintained over the 28-day treatment ...

New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer

... compared first-line XELOX (Xeloda + oxaliplatin) versus FOLFOX-4 (intravenous bolus and infusional ... using a two by factorial design, XELOX + placebo versus XELOX + Avastin (7.5 mg/kg q3w) versus FOLFOX-4 + ...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... compared with docetaxel monotherapy (9.8 versus 7.0 months, respectively). The safety ... cardiac events was 5% in the combination group versus 4% in the monotherapy group (>/= Grade 2 ... - Neutropenia - 66% (Grade 3/4 57%) versus 65% (Grade 3/4 59%), with febrile ...

Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery

... with Femara as the optimal treatment strategy versus tamoxifen EAST HANOVER, N.J., Dec. 11 ... a survival benefit for an aromatase inhibitor versus tamoxifen in the monotherapy setting immediately ... early significant reduction in distant metastases versus tamoxifen, at a median duration of follow-up of ...

New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures

... extended-release tablets comparing tolerability versus levetiracetam immediate release (IR) and ... XR is associated with any tolerability advantages versus the same daily dose of levetiracetam IR. ... once-daily had lower rates of some adverse events versus levetiracetam IR twice-daily. -- In ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... less clinically relevant bleeding (5.2 percent versus 7.3 percent) and less major bleeding (0.8 percent versus 3.8 percent) in those treated with ... of recurrent venous thromboembolism (2.3 percent versus 3.2 percent) and fatal or non-fatal pulmonary ...

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting

... rates in the FCR arm (24 percent versus 13 percent, respectively). While median overall ... were similar in each treatment arm (50 percent versus 48 percent, respectively). Overall, the FCR ... darbepoetin alfa plus red blood cell transfusions versus red blood cell transfusions alone for the ...

Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome

... allopurinol for three days, with one day overlap) versus allopurinol alone, which showed a reduction in ... uric acid levels for the sequential combination versus allopurinol alone (p=0.06). Tumor lysis ... plasma uric acid >7.5mg/dL was 90% with Elitek versus 53% with allopurinol and 77% with ...

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

... ed Study Comparing Rituximab and Dexamethasone versus Dexamethasone Alone in ITP: Results of ... arm (2 percent in dexamethasone arm versus 6 percent in dexamethasone-plus-rituximab arm). ... compared with the traditional arm (28.7 percent versus 9.5 percent); however, no life-threatening or ...

Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress

... Statistically significant reduction in pain versus Bup/epi in patients receiving EXPAREL 450mg at ... in both EXPAREL 300mg and 450mg patient groups versus active control, 6.4 vs. 7.8 pain intensity and ... in the EXPAREL 450mg group avoided all opioid use versus zero percent (0%) of patients in the active ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... Phase III, Randomized, Open-Label Study of 400 Mg versus 800 Mg of Imatinib Mesylate in Patients with ... International Randomized Study of Interferon versus STI571 (IRIS) 7-Year Follow-up: Sustained ... the upper limit of normal at 2 consecutive visits versus five (1.7%) patients treated with deferoxamine. ...

Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD

... awakening-free nights, and rescue medication use versus placebo.(1) -- Both doses of SYMBICORT were ... mcg only), and rescue medication use versus formoterol.(3) -- Both doses of SYMBICORT were well-tolerated versus formoterol and placebo for up to 12 months.(4) ...

Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections

... test-of-cure visit was 82.2 percent for iclaprim versus 85.3 percent for linezolid in the intent-to-treat ... were: gastrointestinal disorders (7.4 percent versus 10.4 percent for iclaprim and linezolid, ... and administration site conditions (4.2 percent versus 3.9 percent); nervous system disorders ...

SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery

... group and the PCI group (13.6 percent for CABG versus 15.8 percent for PCI, p=0.44), as well as similar ... MI) for the two groups (9.1 percent for CABG versus 7.0 percent for PCI, p=0.29). As expected, ... higher in the PCI group (12.0 percent for PCI versus 6.7 percent for CABG, p=0.02), while the rate ...

Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain

... patients in the QID group had a clinical response versus 25.0% of the placebo QID group (P < 0.0001); ... the Durezol BID patients had a clinical response versus 42.5% of patients in the placebo BID group (P ... statistically significant for the Durezol groups versus the placebo groups in both the QID and ...

Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008

... the clinical efficacy and safety of Genous versus a sirolimus-eluting stent and a bare metal stent ... of Endothelial Progenitor Cell Capture Stent versus Sirolimus-Eluting Bioabsorbable Polymer-Coated Stent versus Bare Metal Stents in Patients Undergoing Primary ...

Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS

... Disability Status Scale (EDSS), with early versus delayed treatment. This effect first appeared at ... to patients with delayed treatment, (0.21 versus 0.27) despite the latter receiving at least three ... 2008. (2) Kappos L et al. Effect of early versus delayed interferon beta-1b treatment on ...

Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings

... achieved significant reductions (88%) in thrombus versus the polyurethane (Carbothane(TM)) control (data ... showed a significant reduction in thrombus versus a standard polyurethane control, and were not statistically different in antithrombotic efficacy versus a commercially available heparin ...

Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin

... (bolus insulin) produced greater A1C reductions versus pre-mixed insulin in people with type 2 diabetes. ... compared to pre-mixed insulin (68 (47%) versus 43 (28%); p=0.0004). LANTUS(R)/APIDRA(R) provided ... costs with insulin glargine plus glulisine versus pre-mix - a prospective, observational study with ...

Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults With Asthma

... percentage of patients receiving SYMBICORT versus those receiving budesonide pMDI and placebo ... begin to work (except for SYMBICORT versus budesonide pMDI in Study 1 [P=.073]).(1) The ... of SYMBICORT(R) (160/4.5 micrograms) versus its Mono-Products (budesonide and formoterol) in ...

Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets

... a 34.2 percent change from baseline (p=0.067, versus placebo) was seen; by Week 16, a 62.4 percent improvement from baseline was observed (p=0.038, versus placebo), showing a durable response four weeks ... an 11.2 percent change from baseline (p=0.032, versus placebo), and remained significant at Week 16 ...

Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study

... of aortic valve disease events alone (308 versus 326; HR 0.97; 95% CI 0.83 to 1.14). The ... (15.7%) in the simvastatin plus ezetimibe group versus 187 (20.1%) in the placebo group. The study ... than among those assigned placebo (93 [9.9%] versus 65 [7.0%]; unadjusted p=0.03), and there were ...
Other Contents
(Date:7/10/2014)... Intelligence today released forecasts from "The Global National eID ... for National Electronic ID (eID) programs will generate $54 billion ... number of National eID cards in circulation will double from ... with its vast population, will dominate the market representing nearly ... Europe trails a distant second at 11%. ...
(Date:7/10/2014)... for Basic Science (IBS), the main organization of the ... has announced that a group of researchers, led by ... in the field of optogenetics that can remotely control ... technology "OptoTrk" and it has succeeded with neuronal differentiation ... is that it requires only light to activate neuronal ...
(Date:7/10/2014)... even improve the state of fisheries resources in ... Mediterranean has deteriorated over the past 20 years. ... reported in the Cell Press journal Current ... stringent monitoring of Mediterranean fishing activities, better enforcement ... Mediterranean waters. , Their data show that the ...
Breaking Biology News(10 mins):National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2New optogenetic tool for controlling neuronal signalling by blue light 2Mediterranean fish stocks show steady decline 2
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Nature, not ... intelligence of individual chimpanzees, a new study finds. ... it comes to cognitive [thinking] abilities in chimpanzees," William ... Atlanta, said in a news release from the journal ... give insight into the evolution of intelligence in humans, ...
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Men who ... aggressive prostate cancer, a new study suggests. But ... several urologists not involved with the study said more ... are truly accurate. For the study, Harvard researchers ... were followed for 24 years, starting in 1986. During ...
(Date:7/10/2014)... More than 200 experts on aggression, who research issues ... attend the 21st World Meeting of the International Society ... Hotel, July 15-19. , Georgia State University is hosting ... year on alternating continents. , "We are excited to ... different countries, which will help produce fresh ideas about ...
(Date:7/10/2014)... of Health and Human Services (HHS) has announced a ... Seidman Cancer Center totaling $4.7 million to support a ... with complex cancer. , Titled "Evidence-Conformant Oncology Care," ... UH to enhance care for adult cancer patients with ... health care utilization. , "We believe that ...
(Date:7/10/2014)... shown that more severe illness and even death are ... infection after developing influenza. Now, however, a team of ... if you reverse the order of infection, the bacteria ... protect against a bad case of the flu. ... which is described as a bacterial virulence factor, might ...
Breaking Medicine News(10 mins):Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2
Other TagsOther Tags